Carevive Blog

The study focuses on multiple myeloma patients and explores the relationship between frailty status and various health outcomes, including symptom burden, physical function, and quality of life, using ePROs. It finds significant differences in these outcomes based on frailty status, with frail patients experiencing greater challenges. The results emphasize the importance of considering frailty in treatment decisions to enhance patient…

This research uses electronic Patient Reported Outcomes (ePROs) to assess symptom burden, treatment bother, physical function, and quality of life across different frailty statuses in CRC patients. It finds that symptom burden and physical function are worse in frail patients, suggesting a tailored approach in treatment and monitoring could improve outcomes. The study advocates for the use of frailty status…

This study examines the impact of remote symptom monitoring (RSM) platforms on breast cancer treatment by tracking patient-reported outcomes (PROs). It highlights how symptom alerts generated from home-based PRO assessments can prompt timely clinical actions, reducing symptom burden and healthcare resource utilization. The poster shows that these interventions help manage symptoms effectively before patients' next clinical visits.

This poster presents findings on how remote symptom alerts can influence the management of breast cancer by providing real-time data on patient symptoms and quality of life. It details how these alerts lead to immediate and appropriate clinical responses, helping manage symptoms more effectively and potentially improving overall treatment outcomes. The study underscores the value of integrating PROs into routine…

Explore our ONS Congress poster titled "Clinic-based Technology Assessments Capture Additional Symptom Measures and Support Care Innovations".

This study illustrates the feasibility of using remote symptom monitoring for gathering data on frailty status, symptom burden, treatment bother, physical function, and quality of life for patients with AML.